98 related articles for article (PubMed ID: 35406775)
1. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Wawruszak A; Luszczki J; Halasa M; Okon E; Landor S; Sahlgren C; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068438
[TBL] [Abstract][Full Text] [Related]
2. Investigation of co-treatment multi-targeting approaches in breast cancer cell lines.
Longaray JB; Dias CK; Scholl JN; Battastini AMO; Figueiró F
Eur J Pharmacol; 2024 Mar; 966():176328. PubMed ID: 38237714
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer epigenetics: current and evolving treatment.
Purja S; Nguyen DT; Kim E
Breast Cancer; 2024 Jun; ():. PubMed ID: 38861041
[TBL] [Abstract][Full Text] [Related]
4. RIP1 Mediates Manzamine-A-Induced Secretory Autophagy in Breast Cancer.
Wang X; Liu Y; Qin H; Qi G; Chen X; Lyu Y; Han Y
Mar Drugs; 2023 Feb; 21(3):. PubMed ID: 36976201
[TBL] [Abstract][Full Text] [Related]
5. SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors.
Djokovic N; Rahnasto-Rilla M; Lougiakis N; Lahtela-Kakkonen M; Nikolic K
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678624
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Marzęda P; Wróblewska-Łuczka P; Florek-Łuszczki M; Drozd M; Góralczyk A; Łuszczki JJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430670
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat (SAHA) and Breast Cancer: An Overview.
Wawruszak A; Borkiewicz L; Okon E; Kukula-Koch W; Afshan S; Halasa M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572928
[TBL] [Abstract][Full Text] [Related]
8. Valproic Acid and Breast Cancer: State of the Art in 2021.
Wawruszak A; Halasa M; Okon E; Kukula-Koch W; Stepulak A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298623
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells.
Wawruszak A; Luszczki J; Czerwonka A; Okon E; Stepulak A
Cells; 2022 Apr; 11(7):. PubMed ID: 35406775
[TBL] [Abstract][Full Text] [Related]
10. Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Wawruszak A; Okon E; Telejko I; Czerwonka A; Luszczki J
Pharmacol Rep; 2022 Oct; 74(5):1011-1024. PubMed ID: 35900723
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
Wawruszak A; Luszczki J; Okon E; Czerwonka A; Stepulak A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742901
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
[TBL] [Abstract][Full Text] [Related]
13. AGK2 ameliorates mast cell-mediated allergic airway inflammation and fibrosis by inhibiting FcεRI/TGF-β signaling pathway.
Kim YY; Hur G; Lee SW; Lee SJ; Lee S; Kim SH; Rho MC
Pharmacol Res; 2020 Sep; 159():105027. PubMed ID: 32565308
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
